-
Subject Areas on Research
-
A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.
-
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
-
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
-
A genomic approach to identify molecular pathways associated with chemotherapy resistance.
-
A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
-
A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.
-
A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.
-
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
-
A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors.
-
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
-
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.
-
A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
-
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
-
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
-
A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
-
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
-
A reappraisal of loop diuretic choice in heart failure patients.
-
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.
-
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
-
Action potential and QT prolongation not sufficient to cause Torsade de Pointes: role of action potential triangulation.
-
Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.
-
Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.
-
Allergenic ingredients in nail polishes.
-
Alpha1-adrenergic blockers and intraoperative floppy-iris syndrome.
-
Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia.
-
American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.
-
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
-
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
-
Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration.
-
Anticoagulant therapy in unstable angina.
-
Anticoagulation in acute cardiac care in patients with chronic kidney disease.
-
Argatroban "reversal" is caused by nonphysiologic stimulation of coagulation, not activated factor VII.
-
Argatroban and Bivalirudin for Perioperative Anticoagulation in Cardiac Surgery.
-
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.
-
Argatroban for anticoagulation during cardiopulmonary bypass in an infant.
-
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
-
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
-
Augmentation of cardiac contractility mediated by the human beta(3)-adrenergic receptor overexpressed in the hearts of transgenic mice.
-
BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia.
-
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
-
Bcl-xL is an oncogenic driver in colorectal cancer.
-
Blockade of thromboxane/endoperoxide receptor-mediated responses in the pulmonary vascular bed of the cat by sulotroban.
-
Bosentan, an endothelin antagonist, augments hepatic graft function by reducing graft circulatory impairment following ischemia/reperfusion injury.
-
Breaking Cryo-EM Resolution Barriers to Facilitate Drug Discovery.
-
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
-
COX-2-derived prostacyclin modulates vascular remodeling.
-
CaMKII is essential for the proasthmatic effects of oxidation.
-
Calcium/calmodulin transduces thrombin-stimulated secretion: studies in intact and minimally permeabilized human umbilical vein endothelial cells.
-
Calmodulin and the cell cycle: involvement in regulation of cell-cycle progression.
-
Calmodulin-myosin light chain kinase inhibition changes fibroblast-populated collagen lattice contraction, cell migration, focal adhesion formation, and wound contraction.
-
Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?
-
Celecoxib (celebrex) increases canine lower esophageal sphincter pressure.
-
Celecoxib does not delay cutaneous wound healing in haemophilia B mice.
-
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.
-
Central corneal thickness in normal, glaucomatous, and ocular hypertensive eyes.
-
Central corneal thickness.
-
Changes in atrioventricular conduction properties with refractory-period modulation.
-
Changes in calmodulin and its mRNA accompany reentry of quiescent (G0) cells into the cell cycle.
-
Characterization of two labor-induced genes, DSCR1 and TCTE1L, in the pregnant ovine myometrium.
-
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.
-
Clinical Trial in a Dish: Personalized Stem Cell-Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT-Prolonging Drugs.
-
Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor.
-
Coenzyme Q10 and statins in heart failure: the dog that didn't bark.
-
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
-
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
-
Combining targeted agents with modern radiotherapy in soft tissue sarcomas.
-
Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.
-
Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.
-
Comparison of intraocular pressure lowering by topical and systemic carbonic anhydrase inhibitors in the rabbit.
-
Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons.
-
Coordinate regulation of forskolin-induced cellular proliferation in macrophages by protein kinase A/cAMP-response element-binding protein (CREB) and Epac1-Rap1 signaling: effects of silencing CREB gene expression on Akt activation.
-
Copper is required for oncogenic BRAF signalling and tumorigenesis.
-
Cryptococcus neoformans phosphoinositide-dependent kinase 1 (PDK1) ortholog is required for stress tolerance and survival in murine phagocytes.
-
Crystal structures of the fungal pathogen Aspergillus fumigatus protein farnesyltransferase complexed with substrates and inhibitors reveal features for antifungal drug design.
-
Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors
-
Cyclopropane Modification of Trehalose Dimycolate Drives Granuloma Angiogenesis and Mycobacterial Growth through Vegf Signaling.
-
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
-
Daltroban blocks thromboxane responses in the pulmonary vascular bed of the cat.
-
Dangerous liaisons: flirtations between oncogenic BRAF and GRP78 in drug-resistant melanomas.
-
Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities.
-
Development and biological evaluation of ⁹⁹mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers.
-
Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup.
-
Developmental neurotoxicity of perfluorinated chemicals modeled in vitro.
-
Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor.
-
Direct thrombin inhibitors: alternatives to heparin.
-
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.
-
Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation.
-
Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
-
Dofetilide dose reductions and discontinuations in women compared with men.
-
Dual contribution of TRPV4 antagonism in the regulatory effect of vasoinhibins on blood-retinal barrier permeability: diabetic milieu makes a difference.
-
Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors.
-
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
-
Effect of dofetilide on survival in patients with supraventricular arrhythmias.
-
Effect of glaucoma medications on 24-hour intraocular pressure-related patterns using a contact lens sensor.
-
Effect of pazopanib on tumor microenvironment and liposome delivery.
-
Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example.
-
Effects of alpha 1-adrenergic receptor subtype selective antagonists on lower urinary tract function in rats with bladder outlet obstruction.
-
Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis.
-
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
-
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
-
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
-
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
-
Elementary Ca2+ signals through endothelial TRPV4 channels regulate vascular function.
-
Elinogrel: pharmacological principles, preclinical and early phase clinical testing.
-
Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
-
Endogenous ghrelin and 5-HT regulate interdigestive gastrointestinal contractions in conscious rats.
-
Estimating data transformations in nonlinear mixed effects models.
-
Evaluation of the dofetilide risk-management program.
-
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
-
Flow cytometric analysis of nitric oxide production in human neutrophils using dichlorofluorescein diacetate in the presence of a calmodulin inhibitor.
-
Fondaparinux therapy in a hemodialysis patient with heparin-induced thrombocytopenia type II.
-
Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.
-
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
-
Glucose availability and glycolytic metabolism dictate glycosphingolipid levels.
-
HIV-1 gp120 induces anergy in naive T lymphocytes through CD4-independent protein kinase-A-mediated signaling.
-
Heparin-induced thrombocytopenia and cardiac surgery.
-
Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation.
-
Host response to infection: the role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages.
-
How direct-to-consumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior.
-
Identification and inhibitory properties of a novel Ca(2+)/calmodulin antagonist.
-
Identification of Hsp90 Inhibitors with Anti-Plasmodium Activity.
-
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
-
Increase in antibiotic resistance among isolates of Salmonella in the United States, 1967-1975.
-
Induction of miR-132 and miR-212 Expression by Glucagon-Like Peptide 1 (GLP-1) in Rodent and Human Pancreatic β-Cells.
-
Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis.
-
Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.
-
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.
-
Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
-
Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.
-
Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.
-
Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci.
-
International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
-
Intraoperative floppy iris syndrome: report of a case and histopathologic analysis.
-
Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
-
Key roles of necroptotic factors in promoting tumor growth.
-
Local drug delivery of argatroban from a polymeric-metallic composite stent reduces platelet deposition in a swine coronary model.
-
MCC950, a selective NLPR3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation.
-
Management of glaucoma in pregnancy and lactation.
-
Maximal beta3-adrenergic regulation of lipolysis involves Src and epidermal growth factor receptor-dependent ERK1/2 activation.
-
Measuring carotid artery intima-media thickness: simplicity versus complexity?
-
Medical Expulsive Therapy is Useful for Urinary Calculi.
-
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.
-
Melanoma brain metastasis: overview of current management and emerging targeted therapies.
-
Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1.
-
Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
-
Mitochondrial Homeostasis in AML and Gasping for Response in Resistance to BCL2 Blockade.
-
Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
-
Modulation of IA currents by capsaicin in rat trigeminal ganglion neurons.
-
Monitoring direct thrombin inhibitors: time for standardization.
-
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.
-
New Treatment Options for Hepatitis C Virus Infection in End-Stage Kidney Disease: To Treat or Not to Treat.
-
New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.
-
New treatment options for heparin-induced thrombocytopenia.
-
Nuclear receptor LXRalpha is involved in cAMP-mediated human renin gene expression.
-
Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C.
-
Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation.
-
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
-
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
-
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.
-
PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
-
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
-
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.
-
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
-
Pazopanib ameliorates acute lung injuries via inhibition of MAP3K2 and MAP3K3.
-
Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report.
-
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
-
Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia.
-
Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.
-
Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects.
-
Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.
-
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.
-
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.
-
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
-
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
-
Phase I study of pazopanib plus TH-302 in advanced solid tumors.
-
Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.
-
Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study.
-
Phase I trial of pazopanib in patients with advanced cancer.
-
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
-
Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.
-
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
-
Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'?
-
Potentiation of bleomycin lethality by anticalmodulin drugs: a role for calmodulin in DNA repair.
-
Practitioner acceptance of the dofetilide risk-management program.
-
Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia.
-
Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
-
Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project).
-
Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit.
-
Properties of secretin receptor internalization differ from those of the beta(2)-adrenergic receptor.
-
Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.
-
Pyoderma gangrenosum, altered delayed hypersensitivity and polyarthritis.
-
Quantitative analysis of twelve sulfonamides in honey after acidic hydrolysis by high-performance liquid chromatography with post-column derivatization and fluorescence detection.
-
ROC curve estimation under test-result-dependent sampling.
-
Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
-
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).
-
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
-
Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit.
-
Reductive TCA cycle metabolism fuels glutamine- and glucose-stimulated insulin secretion.
-
Regulation of cyclin D1/Cdk4 complexes by calcium/calmodulin-dependent protein kinase I.
-
Releasing the block: setting differentiation free with mutant IDH inhibitors.
-
Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.
-
Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor.
-
Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract.
-
Results of the FUEL Trial.
-
SAHIT Investigators--on the outcome of some subarachnoid hemorrhage clinical trials.
-
Scanning electron microscopical observations of two novel hemostatic polymers.
-
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
-
Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.
-
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
-
Skin tight: macrophage-specific COX-2 induction links salt handling in kidney and skin.
-
Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation.
-
Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach.
-
Stereochemistry and mechanism of the Brønsted acid catalyzed intramolecular hydrofunctionalization of an unactivated cyclic alkene.
-
Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
-
Structural basis of the promiscuous inhibitor susceptibility of Escherichia coli LpxC.
-
Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents.
-
Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors.
-
Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia.
-
Synthesis of isomeric 3-piperidinyl and 3-pyrrolidinyl benzo[5,6]cyclohepta[1,2-b]pyridines: sulfonamido derivatives as inhibitors of Ras prenylation.
-
Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity.
-
Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity.
-
TRPV4 channel contributes to serotonin-induced pulmonary vasoconstriction and the enhanced vascular reactivity in chronic hypoxic pulmonary hypertension.
-
Tamsulosin and the intraoperative floppy iris syndrome.
-
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
-
Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.
-
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
-
The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors.
-
The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.
-
The STAMPEDE trial and celecoxib: how to adapt?
-
The effect of Rho-associated kinase inhibition on the ocular penetration of timolol maleate.
-
The effect of alpha1-adrenergic receptor antagonist tamsulosin (Flomax) on iris dilator smooth muscle anatomy.
-
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
-
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.
-
The effects of argatroban on thrombin generation and hemostatic activation in vitro.
-
The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.
-
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
-
The polymodal ion channel transient receptor potential vanilloid 4 modulates calcium flux, spiking rate, and apoptosis of mouse retinal ganglion cells.
-
The rapid evolution of treatment strategies for hepatitis C.
-
The role of the prostaglandin EP4 receptor in the regulation of human outflow facility.
-
The unanticipated loss of SO2 from sulfonamides in collision-induced dissociation.
-
Therapy of inflammatory bowel disease: what to expect in the next decade.
-
Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma.
-
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial).
-
Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital.
-
Transient receptor potential vanilloid 4 inhibits mouse colonic motility by activating NO-dependent enteric neurotransmission.
-
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
-
Treatment of pneumococcal meningitis with cephaloridine.
-
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
-
Upregulation of AKT1 protein expression in forskolin-stimulated macrophage: evidence from ChIP analysis that CREB binds to and activates the AKT1 promoter.
-
Variability of action potential duration in pharmacologically induced long QT syndrome type 1.
-
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
-
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
-
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
-
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
-
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
-
What to do with acute atrial fibrillation?
-
beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi.
-
beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor.
-
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
-
Keywords of People
-
Chitneni, Satish K.,
Associate Professor in Radiology,
Radiology
-
Cianciolo, George James,
Associate Professor Emeritus of Pathology,
Pathology
-
McLendon, Roger Edwin,
Professor of Pathology,
Pathology
-
Mentz, Robert John,
Associate Professor of Medicine,
Medicine, Cardiology
-
Uronis, Hope Elizabeth,
Associate Professor of Medicine,
Medicine, Medical Oncology
-
Yan, Hai,
Adjunct Professor of Pathology,
Pathology